BackAEON Biopharma Overview

AEON Biopharma Long Term Debt

Track AEON Biopharma's long-term debt ($2.4M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$2.37M
↓ 83.57% YoYΔ $-12.04M vs prior year quarter

Peer average

Loading

AEON Biopharma Long Term Debt History

Loading

AEON Biopharma vs. peers: Long Term Debt Comparison

Loading

AEON Biopharma Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

AEON Biopharma (AEON) FAQ

As of the most recent data (March 2026), AEON shows a long-term debt of $2.4M. That compares with $14M in the prior-year period — down 83.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, AEON's long-term debt is now $2.4M (was $14M) — a 83.6% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether AEON Biopharma is outperforming or lagging.

Tracking AEON's long-term debt over time shows whether AEON Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $2.4M That compares with $14M in the prior-year period — down 83.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has AEON Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $2.4M) with ownership activity and broader fundamentals.